6 results on '"Henri Montaudié"'
Search Results
2. Treatment of Severe Hailey-Hailey Disease With Apremilast
- Author
-
Christine Chiaverini, Julie Kieffer, Jean-Philippe Lacour, Thierry Passeron, Henri Montaudié, and Florence Le Duff
- Subjects
Male ,medicine.medical_specialty ,Pemphigus, Benign Familial ,Biopsy ,Administration, Oral ,Dermatology ,Severity of Illness Index ,Drug Administration Schedule ,law.invention ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Severity of illness ,medicine ,Outpatient clinic ,Humans ,Family history ,Adverse effect ,Skin ,medicine.diagnostic_test ,Dose-Response Relationship, Drug ,business.industry ,Brief Report ,Anti-Inflammatory Agents, Non-Steroidal ,Middle Aged ,medicine.disease ,Thalidomide ,Hailey–Hailey disease ,030220 oncology & carcinogenesis ,Female ,Apremilast ,business ,medicine.drug ,Follow-Up Studies - Abstract
IMPORTANCE: Hailey-Hailey disease (HHD) is a rare, autosomal-dominant acantholytic dermatosis characterized clinically by development of recurrent blisters and erosions in friction areas. Despite progression in our understanding of the molecular genetics of HHD, therapy remains suboptimal and there is no known cure. OBJECTIVE: To determine whether the novel phosphodiesterase-4 inhibitor apremilast is effective in the treatment of HHD. DESIGN, SETTING, AND PARTICIPANTS: Clinical case series of 4 patients with severe, treatment-resistant HHD at an outpatient clinic in the Department of Dermatology of Nice University Hospital, Nice, France. The patients were treated with apremilast; after the initial titration, the dose was 30 mg, twice daily. MAIN OUTCOMES AND MEASURES: Objective clinical response was assessed by the treating dermatologist using the physician global assessment score; recorded adverse effects were monitored throughout the treatment at intervals of 2 to 3 months. RESULTS: Three women and 1 man, with a mean age of 56 years, were treated and followed up for 6 to 10 months. Family history of the disease was noted in 3 (75%) of the cases. The lesions affected the axillary regions (75%), submammary regions (75%), inguinal regions (100%), and back and neck areas (50%). An improvement in the symptoms was reported by all of the patients after a treatment period of 1 month. After 6 months, the improvement of HHD lesions was reported as moderate to almost cleared among the patients. However, 2 patients developed some flares after 6 to 10 months of treatment and stopped apremilast therapy. One of the patients developed uncontrolled diffuse lesions and apremilast was reintroduced, resulting in partial control of her disease. CONCLUSIONS AND RELEVANCE: Apremilast appears to offer a low-risk therapeutic alternative or adjunct in resistant and severe forms of HHD. A prospective controlled trial with long-term follow-up is required to confirm these preliminary observations.
- Published
- 2018
3. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma
- Author
-
Pierre Bory, A. Picard, Thierry Passeron, Jean-Philippe Lacour, Adrien Sanchez, Henri Montaudié, and Xavier Belgodere
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Melanoma ,Dermatology ,Pembrolizumab ,Stage iiib ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Antiphospholipid syndrome ,030220 oncology & carcinogenesis ,Biopsy ,Monoclonal ,medicine ,Neoplasm staging ,business ,Melanoma diagnosis - Published
- 2018
4. Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab
- Author
-
Anne Sudaka, Frederic Peyrade, Emmanuel Chamorey, Nicolas Weinbreck, Jean-Philippe Lacour, A. Picard, Bérengère Dadone, Florence Pedeutour, Gilles Poissonnet, Maxime Benchetrit, Laurence Saudes, Thierry Passeron, Valérie Duranton-Tanneur, Henri Montaudié, Nathalie Cardot-Leccia, and Marc Ettaiche
- Subjects
Male ,Proto-Oncogene Proteins B-raf ,Neuroblastoma RAS viral oncogene homolog ,Oncology ,medicine.medical_specialty ,Skin Neoplasms ,Cetuximab ,Antineoplastic Agents ,Dermatology ,EGFR Gene Mutation ,Bioinformatics ,medicine.disease_cause ,Disease-Free Survival ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,HRAS ,neoplasms ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Point mutation ,Incidence (epidemiology) ,Middle Aged ,digestive system diseases ,ErbB Receptors ,Survival Rate ,Genes, ras ,Treatment Outcome ,030220 oncology & carcinogenesis ,Mutation ,Carcinoma, Squamous Cell ,Female ,France ,KRAS ,business ,Follow-Up Studies ,medicine.drug - Abstract
Importance Cetuximab was recently proposed for advanced cutaneous squamous cell carcinomas (cSCC); however, its efficacy is inconsistent and identification of predictive biomarkers for response is necessary. Objective To search for somatic mutations of the HRAS, KRAS, NRAS, BRAF, and EGFR genes in patients with advanced cSCC treated with cetuximab; and to investigate the efficacy and tolerance of cetuximab according to these mutations. Design, Setting, and Participants A multicentric and retrospective study of 31 patients (22 men, 9 women) with histologically confirmed advanced cSCC carried out in 1 department of dermatology and 2 departments of medical oncology in France between January 2008 and December 2014. The median age of participants was 86 years (range, 48-96 years). Interventions Mutational status was determined by pyrosequencing method, allelic discrimination, or Sanger sequencing. Patients were treated by single-agent cetuximab. Main Outcomes and Measures The primary end point was the incidence of somatic mutations of the RAS, BRAF, and EGFR genes and association of cetuximab efficacy with these mutations was investigated by using Fisher test. Secondary end points were the disease control rate (DCR) at week 6, the progression free-survival (PFS), overall survival (OS), and safety profile of cetuximab. Results Thirty-one samples of cSCC from 31 patients were analyzed. Only 2 RAS mutated samples (6.5%) were identified. The first harbored a NRAS point mutation (c.35G>A) in codon 12, resulting in a p.G12D substitution. The second sample presented a HRAS point mutation (c.38G>T) in codon 13, resulting in a p.G13V substitution. No mutation of KRAS, BRAF, and EGFR genes at the investigated loci was found. Two patients with NRAS and HRAS mutations showed a partial and complete response to cetuximab, respectively. The mean duration of follow-up was 19 months. At week 6, the disease control rate was 67.8%. The median OS was 13 months and the median PFS was 9 months. All patients could continue cetuximab treatment without dose reduction. Conclusions and Relevance Even in elderly patients with advanced cSCC, cetuximab was efficacious and well-tolerated. This suggests that cetuximab is certainly warranted in the treatment of advanced cSCC. However, it is also important to identify tumor specific mutations that may determine response to treatment and prognosis for the disease. We have identified here that the incidence of RAS, BRAF, and EGFR mutations is low in cSCC.
- Published
- 2017
5. Copper Bromide Laser vs Triple-Combination Cream for the Treatment of Melasma
- Author
-
E. Fontas, Jean-Philippe Lacour, Henri Montaudié, Thierry Passeron, Philippe Bahadoran, Houda Hammami Ghorbel, and F. Boukari
- Subjects
Adult ,Bromides ,Male ,medicine.medical_specialty ,Melasma ,Treatment outcome ,Skin Cream ,Tretinoin ,Dermatology ,Severity of Illness Index ,Dexamethasone ,Melanosis ,law.invention ,Randomized controlled trial ,Laser therapy ,law ,medicine ,Triple combination ,Humans ,Single-Blind Method ,Prospective Studies ,business.industry ,Middle Aged ,medicine.disease ,Hydroquinones ,Drug Combinations ,Treatment Outcome ,Copper bromide ,Female ,Laser Therapy ,business ,Copper - Published
- 2015
6. Flexural Agminated Eruptive Nevi in Langerhans Cell Histiocytosis
- Author
-
Henri Montaudié, Pierre Vabres, Philippe Bahadoran, N. Erfan, Candace Ben Signor, Catherine Surinach, Christine Chiaverini, Jean-Philippe Lacour, Maxime Benchetrit, Anne Deville, and Thierry Passeron
- Subjects
Histiocytosis ,Axilla ,medicine.medical_specialty ,medicine.anatomical_structure ,Langerhans cell histiocytosis ,Groin ,business.industry ,medicine ,Nevus ,Dermatology ,medicine.disease ,business - Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.